New Jersey Governor Phil Murphy signed off on a bill allowing cannabis businesses in the state to claim state tax deductions, working around 280E.
The governor of New Jersey (NJ), Phil Murphy (D), recently signed a bill into law which provided licensed cannabis businesses the ability to deduct certain expenses from their state tax returns. It was a partial antidote for the cannabis industry which has been prevented from benefitting from federal deductions under the Internal Revenue Service (IRS) code, 280E.
Most states follow federal law but New Jersey’s new piece of legislation states that a licensed cannabis business’s gross income (1), “shall be determined without regard to section 280E of the [federal] Internal Revenue Code.” These businesses will still be subjected to the IRS 280E, which prevents establishments who illegally sell Schedule I or II drugs from taking part in key tax deductions in their federal filings. In NJ, licensed cannabis industry businesses will be able to experience some state-level relief.
This exciting legislation signed by Governor Murphy stated that it “shall apply to taxable years beginning on or after January 1 following enactment,” (1).
“The continued implementation of 280E placed severe financial constraints on cannabis operators, big and small, by prohibiting them from deducting common business expenses from their taxes,” the New Jersey Cannabis Trade Association said (1). “Now, New Jersey’s licensed cannabis operators will be treated like any other legal enterprise operating in New Jersey, a sense of normalcy that our industry will cherish.”
Last year, a fiscal analysis was performed and showed that the new law would possibly have mixed economic impacts. The decoupling from the federal 280E policy is anticipated to “result in an indeterminate annual loss of revenue” (1) for NJ because cannabis businesses would be qualified for relief from taxes they currently pay.
The Office of Legislative Services (OLS) added that “providing access to these deductions and credits may also help generate more economic activity by cannabis businesses,” and so “the State and local governments that tax cannabis businesses might indirectly realize an indeterminate amount of additional annual revenue,” (1).
Reference
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.